Calcium crystals detected by scanning electronic microscopy in synovial fluid of patients with early knee osteoarthritis. relationships with infiammation and disease severity  by Ramonda, R. et al.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S392characterized by pain and/ or stiffness of knee and/ or hip. They were
included at the ﬁrst visit or within 6 months of the ﬁrst visit to the
general practitioner for these symptoms. Study centers comprise ten
general and university hospitals located in urbanized and semi-
urbanized regions in the Netherlands. A special programwas developed
to minimize loss to follow up, comprising newsletters, website and
organizing symposia to present the results and progress of CHECK. An
overview of measures that are included in the study can be found at our
website www.check-research.com.
Results: After 7 years a total of 105 (10%) participants had dropped out.
Reasons included loss of interest (21%), comorbidity that complicated
participating of CHECK too much (18%), death (12%), contact lost (11%),
costs incurred for the study (5%), and other reasons (33%). Dropouts did
not differ signiﬁcantly from other participants in baseline character-
istics. Over 7 years follow-up clinical characteristics including pain,
stiffness and function of disease-speciﬁc (WOMAC) and the subscales of
generic self-report questionnaire (SF36) on average did not change
signiﬁcantly, although at least half of the patients experienced radio-
graphic progression. Scoring of 5-year follow up is complete: at this
point, 50 % of the participants progressed by at least one Kellgren and
Lawrence grade in the knee, and 25% in the hip. Preliminary analyses
suggest the existence of several clinical and radiological phenotypes.
Conclusions: CHECK is a valuable source of information of early
symptomatic OA with a low loss to follow-up and a multidisciplinary
approach that allows the collections of high-quality data on clinical,
radiological and biochemical variables.
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CALCIUM CRYSTALS DETECTED BY SCANNING ELECTRONIC
MICROSCOPY IN SYNOVIAL FLUID OF PATIENTS WITH EARLY KNEE
OSTEOARTHRITIS. RELATIONSHIPS WITH INFIAMMATION AND
DISEASE SEVERITY
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Purpose: The presence of calcium crystals (CC) in synovial ﬂuid (SF) of
osteoarthritis (OA) is a well known and frequent feature. However, their
role in the pathogenesis of OA is still unclear andmatter of discussion, in
particular as regard the local inﬂammation. The objective of the study
was to evaluate the presence of the most common CC, calcium pyro-
phosphate (dehydrate) (CPP) and basic calcium phosphate (BCP), in SF
of the symptomatic knee OA (KOA, particularly in early disease stage
(<1year) and to investigate their association with local inﬁammation,
disease activityand severity. We performed an ultrasensitive analysis of
SF crystals using the scanning electron microscopy (SEM) and the
routinary method by compensated polarized ligth microscopy (CPLM)
and alizarin red staining.
Methods: Seventy-four (48 F, mean age 64.859.33 yrs, range 50-89
yrs) consecutive outpatients attending theRheumatology Unit, Uni-
versity of Padova with symptomatic KOA (according to the American
College of Rheumatology criteria) underwent knee arthrocentesis. After
optical and CPLM, the SF was analysed by SEM. Total white blood cell
(WBC) count was performed and a cut-off of total WBC was establishedDSPCC 35 m
SF-36 Physical Component Score (n [ 94)
Mean change from baseline to week 12 7.58*
SF-36 Domain Scores (n[ 94)
Physical functioning score mean change from baseline to week 12 5.99*
Role physical score mean change from baseline to week 12 7.71*
Bodily pain score mean change from baseline to week 12 8.87*
General health score mean change from baseline to week 12 2.19
Vitality score mean change from baseline to week 12 4.86*
Social functioning score mean change from baseline to week 12 5.65*
Role emotional score mean change from baseline to week 12 3.87
Mental health score mean change from baseline to week 12 1.77
DSPCC, diclofenac submicron particle containing capsules; TID, three times daily; BID, tw
*P  0.03. Bold values represent scores  minimally clinically important difference (2.
Data above presented as means however, all P-values are compared with placebo and cin < 1000/mm3. Patients’ medical history, clinical features (WOMAC,
Lequense and VAS) X-ray ﬁndings (Kellgren & Lawrence), ultrasound
and power Doppler (PD) signal values were also assessed.
Results: CPP crystals were identiﬁed in 32.4% by CPLM and in 31.1% by
SEM. Alizarin was positive in 36.5% of the samples. BCP were found in
13.5% by SEM. CPP and BCP crystals were simultaneously positive in
8.1% of the samples by SEM. The study population was divided into
three groups depending on disease duration (group A <1 yr; group B 1-
5 yrs; group C > 5 yrs). The SF volume (p¼0.0008) was signiﬁcantly
different in the group Awith respect to B and C groups. The SFWBC was
higher during the early stages of disease (group A), although not sig-
niﬁcant, with respect to B and C groups. Moreover, the presence of CC in
group A correlated signiﬁcantly with SF WBC (p¼0.048) and % of PMN
(p¼0.033) with respect to those without CC in the same group. PD
resulted positive in 43.24% of all the patients, 62.5% of these were CCþ
according to SEM (p<0.0001).
Conclusions: The presence of CC in SF, also when detected in early OA
stages, was associated with a higher degree of local inﬂammation, so
suggesting that they may play a role of in eliciting an inﬂammatory
reaction, which may be crucial in OA pathogenesis.
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A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF LOWER-DOSE
DICLOFENAC CAPSULES IN PATIENTS WITH OSTEOARTHRITIS PAIN:
IMPACT ON PATIENT-REPORTED OUTCOMES
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Purpose: Non-steroidal anti-inﬂammatory drugs (NSAIDs) are fre-
quently prescribed for management of osteoarthritis (OA) pain and
diclofenac is the most frequently used prescription and over-the-
counter NSAID worldwide. NSAIDs, including diclofenac, are asso-
ciated with serious dose-related gastrointestinal, cardiovascular, and
renal adverse events. As a result, the US Food and Drug Administration
and international health authorities have encouraged the use of
NSAIDs at the lowest effective dose for the shortest possible duration.
Diclofenac submicron particle containing capsules (DSPCC) consisting
of submicron drug particles and a proprietary combination of exci-
pients were developed using SoluMatrix Fine Particle Technology to
provide efﬁcacy at lower doses than commercially available diclofenac
drug products and are licensed for treatment of mild-to-moderate
acute pain in adults. In a randomized controlled phase 3 trial (RCT) in
patients with pain due to OA of the knee or hip, DSPCC 35 mg three
times daily (TID) signiﬁcantly reducedWestern Ontario and McMaster
University Osteoarthritis Index (WOMAC) pain subscale scores (P ¼
0.0024) compared with placebo, with non-statistical beneﬁt for the
BID dose (P ¼ 0.0795). We present results of patient-reported out-
comes from this study.
Methods: This 12-week RCT enrolled 305 patients 41 to 90 years of age
with clinically and radiologically conﬁrmed (Kellgren-Lawrence grade
II-III) OA of hip or knee. Patients were chronic NSAID or acetaminophen
users with WOMAC pain subscale scores 40 mm by 100-mm Visual
Analog Scale at baseline and a documented OA ﬂare (15-mm increase)
following NSAID or acetaminophen discontinuation. Eligible patientsg TID (n [ 98) DSPCC 35 mg BID (n [ 104) Placebo (n [ 103)
(n [ 100) (n [ 100)
7.02* 3.87
(n[ 100) (n[ 100)
5.74* 2.83
6.60 4.39
9.25* 5.61
0.92 1.29
4.49* 1.94
4.44 3.07
2.68 3.60
2.18 1.75
ice daily; SF-36, Medical Outcomes Survey Short Form 36 (SF-36), version 2.
5 for physical component score; 5.0 for SF-36 domain scores).
alculated from least-squared mean changes from baseline.
